Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $275000.0.

  • Exagen's Capital Expenditures rose 8707.48% to $275000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $945000.0, marking a year-over-year increase of 9894.74%. This contributed to the annual value of $717000.0 for FY2024, which is 1340.58% down from last year.
  • Exagen's Capital Expenditures amounted to $275000.0 in Q3 2025, which was up 8707.48% from $146000.0 recorded in Q2 2025.
  • Over the past 5 years, Exagen's Capital Expenditures peaked at $1.7 million during Q1 2022, and registered a low of $2000.0 during Q3 2023.
  • In the last 5 years, Exagen's Capital Expenditures had a median value of $324000.0 in 2023 and averaged $464736.8.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 9977.25% in 2023, then soared by 725000.0% in 2024.
  • Over the past 5 years, Exagen's Capital Expenditures (Quarter) stood at $1.1 million in 2021, then crashed by 61.84% to $406000.0 in 2022, then tumbled by 73.89% to $106000.0 in 2023, then soared by 228.3% to $348000.0 in 2024, then fell by 20.98% to $275000.0 in 2025.
  • Its Capital Expenditures stands at $275000.0 for Q3 2025, versus $146000.0 for Q2 2025 and $176000.0 for Q1 2025.